Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Adamis Pharmaceuticals (ADMP) Prices 2M Common Offering at $5/Share
-
Adamis Pharmaceuticals Announces Pricing of Public Offering of Common Stock
-
Brainstorm Cell Therapeutics (BCLI) Enters 2.5M Common Warrant Exercise Agreement
-
Maxim Group Downgrades Ralph Lauren (RL) to Hold on Currency and Macro Concerns
-
PlacementTracker Publishes 2014 PIPE Market League Tables
-
Cesca Therapeutics' (KOOL) IDE Delayed but Next Steps Achievable, Says Maxim (Correct)
-
Athersys (ATHX) Closes in on Major Milestone - Maxim
-
Sucampo's (SCMP) Rescula Faces Generic Challenge, But It's Not a Factor - Maxim Group
-
Check-Cap Ltd. (CHEK) Files $15.75M IPO
-
Maxim Group Starts Quest Resource (QRHC) at Buy
-
Achillion (ACHN) Bullish Stance Reiterated at Maxim Group; Viable Nuc and 'Best in Class' NS5A
-
Have A Little Faith in Gilead (GILD), Says Maxim Group
-
Tekmira Pharma (TKMR) PT Cut to $21 at Maxim Group; 'Buy' Maintained
-
Investors Should Have More Faith in Gilead Sciences (GILD), Maxim Group Says
-
Increased BARDA Funding a Validation for Cytori (CYTX) ADRC Celution System, Maxim Group Says
-
GlaxoSmithKline (GSK) Shingles Vaccine News a Win for Agenus (AGEN), Maxim Group Says; PT to $10
-
Maxim Group Sees Overreaction in Sophiris Bio (SPHS)
-
BioLineRx (BLRX) PT Raised to $8 at Maxim Group
-
Cytori Therapeutics (CYTX) Price Target Lifted to $6 at Maxim Group
-
Maxim Group Downgrades Medley Capital (MCC) to Hold
-
J. C. Penney (JCP) Stores So Dead You Wouldn't Even Know It's Christmas - Analyst
-
Notable Analyst Rating Changes 12/5: (POT) (VOD) (YHOO) Upgraded; (GOOG) (EXP) (EMN) Downgraded
-
Pre-Open Stock Movers 12/05: (ALSK) (VTSS) (SYNA) (ULTA) Higher; (DLIA) (FIVE) (SPWH) (BIG) Lower (more...)
-
Maxim Group Starts TubeMogul, Inc (TUBE) at Buy
-
Maxim Group Starts Rocket Fuel (FUEL) at Sell
-
Maxim Group Starts WNS (Holdings) (WNS) at Buy
-
StemCells, Inc. Hosts Leading Biotech Investors and Analysts at Inaugural Event
-
Momenta (MNTA) More than Just Copaxone, Maxim Group Says
-
IsoRay (ISR) Brain Cancer Results 'Impressive' - Maxim Group
-
Maxim Group Downgrades Energen (EGN) to Hold
-
Maxim Group Downgrades Callon Petroleum (CPE) to Hold
-
Vertex (VRTX) PT Raised to $148 at Maxim Group; CF Franchise Worth a Lot More
-
ADMA Biologics (ADMA) PT Raised to $18 at Maxim Group
-
Keryx Biopharma (KERX) Price Target Raised to $32 at Maxim
-
Notable Analyst Rating Changes 11/25: (TJX) (PBR) (UTX) Upgraded; (P) (CYBR) (NFLX) Downgraded
-
Maxim Group Starts ManTech (MANT) at Buy
-
New York Mortgage Trust (NYMT) Prices 13M Common Offering at $7.94/Share
-
Maxim Group Upgrades Ross Stores, Inc. (ROST) to Hold
-
Applied DNA Sciences (APDN) Closes 2.8M Common, Warrants Offering
-
Urban Outfitters (URBN) PT, Estimates Cut at Maxim Group
-
Maxim Group Maintains Bullish Stance on ImmunoCellular (IMUC) Following Review of SNO Data and Plans for Phase III
-
Streetinsider.com's Hot Lunchtime Reads 11/18: (MBI) (INTC) (TJX) (NBS)
-
NeoStem (NBS) Data Viewed as 'Good' at Maxim Group
-
Maxim Group Sees Tougher Comps Weighing on JCPenney (JCP) Shares
-
Bio-Path Holdings (BPTH) Bullish Stance Reiterated at Maxim Group Post Q3
-
Maxim Group Starts Foamix Pharmaceuticals (FOMX) at Buy
-
Notable Analyst Rating Changes 11/13: (GNW) (AMAT) (BRCM) Upgraded; (MRVL) (M) (BMY) Downgraded
-
Omeros (OMER)PT Raised at Maxim Group on Better Omidria Pricing
-
Maxim Group Starts VMware (VMW) at Buy
-
Maxim Group Starts EMC (EMC) at Hold

